Bloomage Biotech(SH:688363) 智通财经网·2025-09-10 02:33Core Viewpoint - Saint Noble Pharmaceuticals-B (02257) has seen a significant increase in its stock price, with a year-to-date rise exceeding 530% as of the latest report [1] Group 1: Stock Performance - The stock price of Saint Noble Pharmaceuticals rose by over 9%, currently trading at 22.06 HKD with a trading volume of 29.72 million HKD [1] - The cumulative increase in stock price for the year has surpassed 530% [1] Group 2: Investment and Strategic Partnership - Saint Noble Pharmaceuticals announced a placement of 17.35 million new shares at a discount of 19.84% to four investors, including Huaxi Biotechnology (Hong Kong) [1] - Huaxi Biotechnology plans to invest approximately 138 million CNY through its wholly-owned subsidiary, acquiring about 9.44% of Saint Noble Pharmaceuticals post-placement [1] - The investment aims to advance research and commercialization in medical aesthetics, aging intervention, and regenerative medicine, particularly focusing on the STP705 targeted fat reduction project and other siRNA-based medical aesthetic assets [1] - Huaxi Biotechnology emphasizes its role as a strategic investor, indicating potential for further business collaboration with Saint Noble Pharmaceuticals [1]